Interferon-induced depression: strategies in treatment

Area of Science:

• Immunology
• Psychiatry
• Pharmacology

Background:

• Interferon (IFN) is a pro-inflammatory cytokine used to treat viral infections, hematological disorders, and skin cancers.
• IFN therapy frequently causes depression, reducing treatment tolerability and adherence.
• Early diagnosis and management of IFN-induced depression are crucial for patient outcomes.

Purpose of the Study:

• To review the diagnosis and management of depression induced by Interferon (IFN) therapy.
• To highlight the effectiveness of antidepressants in treating IFN-induced depression.
• To provide guidance on managing IFN-induced depression in various patient populations.

Main Methods:

• Literature review of studies on IFN therapy and associated depression.
• Analysis of treatment strategies, including antidepressants and mood stabilizers.
• Evaluation of risk factors and prophylactic measures for IFN-induced depression.

Main Results:

• IFN-induced depression is highly responsive to antidepressant treatment, often with benefits seen at low doses and within weeks.
• Both SSRIs and non-SSRIs show efficacy, but careful consideration of antidepressant risks and side effects is necessary.
• For patients with a history of bipolar disorder, antidepressants must be combined with a mood stabilizer.
• Prophylactic antidepressant treatment may reduce the likelihood of IFN-induced depression in vulnerable patients.

Conclusions:

• IFN-induced depression is a manageable side effect that should not halt treatment.
• Timely diagnosis, appropriate antidepressant selection, and consideration of co-existing conditions are vital.
• Effective management strategies ensure continued IFN therapy for most patients.